Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
1 raison identifiée
Auteur de référence en rhumatologie
50 articles scientifiques publiés — un praticien à la pointe de la recherche
✨ Génération du profil synthétique IA en cours…
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2010
Abstract Patients treated with bisphosphonates for osteoporosis may discontinue or require a switch to other therapies. Denosumab binds to RANKL and is a potent inhibitor of bone resorption that has been shown to increase bone mineral density (BMD) and decrease fracture risk in postmenopausal women with osteoporosis. This was a multicenter, international, randomized, double-blind, double-dummy study in 504 postmenopausal women ≥ 55 years of age with a BMD T-score of −2.0 or less and −4.0 or more who had been receiving alendronate therapy for at least 6 months. Subjects received open-label branded alendronate 70 mg once weekly for 1 month and then were randomly assigned to either continued weekly alendronate therapy or subcutaneous denosumab 60 mg every 6 months and were followed for 12 months. Changes in BMD and biochemical markers of bone turnover were evaluated. In subjects transitioning to denosumab, total hip BMD increased by 1.90% at month 12 compared with a 1.05% increase in subjects continuing on alendronate (p < .0001). Significantly greater BMD gains with denosumab compared with alendronate also were achieved at 12 months at the lumbar spine, femoral neck, and 1/3 radius (all p < .0125). Median serum CTX levels remained near baseline in the alendronate group and were significantly decreased versus alendronate (p < .0001) at all time points with denosumab. Adverse events and serious adverse events were balanced between groups. No clinical hypocalcemic adverse events were reported. Transition to denosumab produced greater increases in BMD at all measured skeletal sites and a greater reduction in bone turnover than did continued alendronate with a similar safety profile in both groups. Copyright © 2010 American Society for Bone and Mineral Research
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2012
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2012
Abstract Denosumab reduces the risk of new vertebral and nonvertebral fractures. Previous trials suggest that the efficacy of antiresorptives on fractures might differ by patients' characteristics, such as age, bone mineral density (BMD), and fracture history. In the FREEDOM study, 7808 women aged 60 to 90 years with osteoporosis were randomly assigned to receive subcutaneous injections of denosumab (60 mg) or placebo every 6 months for 3 years. New vertebral and nonvertebral fractures were radiologically confirmed. Subgroup analyses described in this article were prospectively planned before study unblinding to evaluate the effect of denosumab on new vertebral and nonvertebral fractures across various subgroups. Compared with placebo, denosumab decreased the risk of new vertebral fractures in the overall study population over 3 years. This effect did not significantly differ for any of the nine subgroups analyzed (p > 0.09 for all potential interactions). Denosumab also reduced all nonvertebral fractures by 20% in the full study cohort over 3 years. This risk reduction was statistically significant in women with a baseline femoral neck BMD T-score ≤ −2.5 but not in those with a T-score > −2.5; in those with a body mass index (BMI) < 25 kg/m2 but not ≥ 25 kg/m2; and in those without but not with a prevalent vertebral fracture. These differential treatment effects were not explained by differences in BMD responses to denosumab. Denosumab 60 mg administered every 6 months for 3 years in women with osteoporosis reduced the risk of new vertebral fractures to a similar degree in all subgroups. The effect of denosumab on nonvertebral fracture risk differed by femoral neck BMD, BMI, and prevalent vertebral fracture at baseline. © 2012 American Society for Bone and Mineral Research
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
The Journal of allergy and clinical immunology · 2026 · Journal Article
Montero-Hernández JE, Vibhushan S, Bratti M, Bex-Coudrat J, et al.
The Journal of experimental medicine · 2026 · Journal Article
Bex J, Peter V, Saji C, Dupont C, et al.
Nature communications · 2024 · Journal Article
Tchen J, Simon Q, Chapart L, Thaminy MK, et al.
Frontiers in immunology · 2022 · Journal Article
Tchen J, Simon Q, Chapart L, Pellefigues C, et al.
Clinical and experimental rheumatology · 2022 · Journal Article
Péan de Ponfilly-Sotier M, Jachiet V, Benhamou Y, Lahuna C, et al.
mBio · 2021 · Journal Article
Benhamou S, Rahioui I, Henri H, Charles H, et al.
International journal of molecular sciences · 2020 · Journal Article
Vibhushan S, Bratti M, Montero-Hernández JE, El Ghoneimi A, et al.
Kidney international · 2020 · Journal Article
Madjene LC, Danelli L, Dahdah A, Vibhushan S, et al.
Science signaling · 2018 · Journal Article
Madera-Salcedo IK, Danelli L, Tiwari N, Dema B, et al.
Frontiers in immunology · 2018 · Journal Article
Ngo Nyekel F, Pacreau E, Benadda S, Msallam R, et al.
PloS one · 2017 · Journal Article
Kassas-Guediri A, Coudrat J, Pacreau E, Launay P, et al.
Nature communications · 2017 · Journal Article
Mkaddem SB, Murua A, Flament H, Titeca-Beauport D, et al.
Geriatrie et psychologie neuropsychiatrie du vieillissement · 2016 · Journal Article
Souberbielle JC, Benhamou CL, Cortet B, Rousière M, et al.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2016 · Clinical Trial, Phase II
Rizzoli R, Benhamou CL, Halse J, Miller PD, et al.
European journal of pharmacology · 2016 · Journal Article
Blank U, Charles N, Benhamou M
Joint bone spine · 2015 · Journal Article
Bousson V, Bergot C, Sutter B, Thomas T, et al.
Molecular immunology · 2015 · Journal Article
Madjene LC, Pons M, Danelli L, Claver J, et al.
PloS one · 2014 · Journal Article
Kassas A, Moura IC, Yamashita Y, Scheffel J, et al.
The Journal of clinical investigation · 2014 · Journal Article
Dahdah A, Gautier G, Attout T, Fiore F, et al.
Joint bone spine · 2014 · Journal Article
Blain H, Rolland Y, Beauchet O, Annweiler C, et al.
The Journal of clinical endocrinology and metabolism · 2014 · Clinical Trial
Breuil V, Panaia-Ferrari P, Fontas E, Roux C, et al.
Joint bone spine · 2013 · Journal Article
Maurel DB, Boisseau N, Pallu S, Rochefort GY, et al.
Calcified tissue international · 2013 · Journal Article
McClung MR, Benhamou CL, Man Z, Tlustochowicz W, et al.
PloS one · 2012 · Journal Article
Pallu S, Rochefort GY, Jaffre C, Refregiers M, et al.
Joint bone spine · 2012 · Journal Article
Fouque-Aubert A, Boutroy S, Marotte H, Vilayphiou N, et al.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2012 · Journal Article
Guillerminet F, Fabien-Soulé V, Even PC, Tomé D, et al.
Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry · 2012 · Journal Article
Briot K, Benhamou CL, Roux C
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2012 · Clinical Trial, Phase III
Reginster JY, Kaufman JM, Goemaere S, Devogelaer JP, et al.
Journal of the American Academy of Dermatology · 2012 · Case Reports
Rünger TM, Adami S, Benhamou CL, Czerwiński E, et al.
Frontiers in immunology · 2011 · Journal Article
Beghdadi W, Madjene LC, Benhamou M, Charles N, et al.
Medical physics · 2010 · Journal Article
Peyrin F, Attali D, Chappard C, Benhamou CL
Bone · 2010 · Journal Article
Briot K, Kolta S, Fechtenbaum J, Said-Nahal R, et al.
Bone · 2010 · Journal Article
Seeman E, Boonen S, Borgström F, Vellas B, et al.
Bone · 2010 · Comparative Study
Guillerminet F, Beaupied H, Fabien-Soulé V, Tomé D, et al.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2010 · Journal Article
Roux C, Fechtenbaum J, Kolta S, Said-Nahal R, et al.
Calcified tissue international · 2016 · Journal Article
Langdahl BL, Ljunggren Ö, Benhamou CL, Marin F, et al.
Current medical research and opinion · 2014 · Journal Article
Ljunggren O, Benhamou CL, Dekker J, Kapetanos G, et al.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2012 · Journal Article
Annals of internal medicine · 2025 · Journal Article
Terrier B, Pugnet G, de Moreuil C, Bonnotte B, et al.
Annals of the rheumatic diseases · 2024 · Journal Article
Delestre F, Charles P, Karras A, Pagnoux C, et al.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2013 · Journal Article
McClung MR, Zanchetta JR, Racewicz A, Roux C, et al.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2012 · Journal Article
McClung MR, Miller PD, Brown JP, Zanchetta J, et al.
The Journal of allergy and clinical immunology · 2021 · Journal Article
Lamri Y, Vibhushan S, Pacreau E, Boedec E, et al.
The Journal of rheumatology · 2014 · Clinical Trial, Phase III
Genovese MC, van der Heijde DM, Keystone EC, Spindler AJ, et al.
Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference · 2010 · Journal Article
Jennane R, Almhdie-Imjabber A, Hambli R, Ucan ON, et al.
Journal of medical systems · 2010 · Journal Article
Akgundogdu A, Jennane R, Aufort G, Benhamou CL, et al.
Frontiers in pediatrics · 2023 · Journal Article
Charles MA, Ancel PY, Simeon T, Marchand-Martin L, et al.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2012 · Journal Article
Maurel DB, Boisseau N, Benhamou CL, Jaffre C
Arthritis care & research · 2011 · Journal Article
Rist S, Sellam J, Hachulla E, Sordet C, et al.
Annals of the rheumatic diseases · 2024 · Journal Article
Delestre F, Charles P, Karras A, Pagnoux C, et al.
McClung MR, Boonen S, Törring O, Roux C, et al.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2010 · Clinical Trial, Phase III
Kendler DL, Roux C, Benhamou CL, Brown JP, et al.